z-logo
open-access-imgOpen Access
Tivozanib (Fotivda®)
Author(s) -
Michelle Sproat
Publication year - 2021
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000789328.80500.8b
Subject(s) - sorafenib , medicine , renal cell carcinoma , tyrosine kinase inhibitor , refractory (planetary science) , tyrosine kinase , cancer research , kinase , oncology , cancer , receptor , chemistry , biology , biochemistry , astrobiology , hepatocellular carcinoma

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom